# LFVN earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/LFVN) · [Earnings tab](https://www.lopjlb.com/stock/LFVN?tab=earnings) Updated: 2026-08-28T07:35:08 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for LFVN, management tone moved from +0.60 (2024 Q4) to +0.70 (2026 Q3). Latest guidance stance: lowered. Latest desk line: LifeVantage Q3 2026 revenue fell 25% as MindBody sales slumped, but management stays upbeat on Shopify rollout, new CEO, patent and consultant incentives, while guidance is lowered to the bottom of prior ranges. ## Latest CallCard · Q3 LifeVantage Q3 2026 revenue fell 25% as MindBody sales slumped, but management stays upbeat on Shopify rollout, new CEO, patent and consultant incentives, while guidance is lowered to the bottom of prior ranges. **Guidance:** lowered — Guidance adjusted to the lower end of previously issued ranges due to competitive dynamics and current sales trends. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Management expressed confidence in product portfolio, consultant community, upcoming Shopify launch and growth opportunities, describing the business as solid and future outlook positive. ### Demand visibility Demand mixed; health‑wellness market expanding but key product sales declined. Revenue fell 25% driven by MindBody GLP‑1 decline; consultant count dropped in Americas, yet strong engagement from consultants and new VIP program suggest upside. ### Margins / costs Gross margin slipped to 79% from 81%. Margin pressure from higher shipping, warehouse expenses and inventory obsolescence; non‑GAAP gross profit 79.4%. ### Capital allocation Share repurchases continued and dividend increased. Repurchased ~206,000 shares for $1 million in the quarter; $59 million remaining under $60 million buyback; declared $0.05 dividend, an 11% increase. ### Milestones - **Shopify integration** [at_risk]: Targeting launch later this year; rollout expected Q4/Q1 with staggered international implementation. - **VIP bonus program** [new]: First 12‑month volume growth incentive announced to drive consultant leadership and retention. - **Healthy Glow Essentials Stack patent** [new]: U.S. patent granted, validating scientific innovation behind Protandim and TrueScience Liquid Collagen. - **Appointment of Terrence Moorehead as CEO** [new]: Will join in August, bringing 30+ years of direct‑selling leadership. - **Momentum Academy Las Vegas** [delivered]: Three‑day event reinforced consultant engagement and announced VIP program. ### Fears / risks - **Sales decline**: MindBody GLP‑1 system sales fell sharply, driving a 25% revenue drop. - **Consultant attrition**: Consultant count in Americas fell from 32,000 to 30,000, raising concerns about field strength. - **Margin pressure**: Gross profit percentage fell to 79% due to higher shipping, warehouse and inventory obsolescence costs. - **Cash flow shortfall**: Cash from operations $5.5 M lower than prior year, with uncertainty about Q4 cash generation. - **Competitive dynamics**: Competitive pressures in the GLP‑1 market cited as factor for lowered guidance. - **CapEx sustainability**: Ongoing $1 M quarterly CapEx for Shopify could strain cash if rollout delayed. - **Product pipeline risk**: Next hero product launch not detailed, timing uncertain beyond October convention. - **Shareholder expectations**: Lowered guidance to lower end of prior range may disappoint investors. ### Key quotes > “We plan to start launching Shopify later this year, and we're excited about the prospects as we roll the Shopify launch through our markets.” > “We now expect to end fiscal 2026 with revenue, adjusted EBITDA and adjusted earnings per share close to the lower end of our previously issued guidance range.” > “For the third quarter of fiscal 2026, we delivered net revenue of $43.7 million, which was down 25.2% compared to $58.4 million in the third quarter of fiscal 2025.” > “Definitely not a number we're excited about, but I think what has us all really excited, myself included, is just the engagement that we're starting to see, the activity that we're starting to see.” — Kristen Cunningham > “We're targeting to get things in place later, probably not by the end of Q4, but into rolling into Q1, and there'll be a staggered approach as we roll it out internationally.” ## Quarter one-liners - **2026 Q3:** LifeVantage Q3 2026 revenue fell 25% as MindBody sales slumped, but management stays upbeat on Shopify rollout, new CEO, patent and consultant incentives, while guidance is lowered to the bottom of prior ranges. - **2026 Q2:** LifeVantage Q2 revenue fell 27.8% as GLP‑1 competition intensified, prompting an inventory reserve, but LoveBiome integration, new product launches and a $60M buyback keep management optimistic about H2 growth. - **2026 Q1:** LifeVantage Q1 FY26 revenue flat at $47.6M; LoveBiome acquisition closed Oct 1, integration complete Nov 1; FY26 guidance maintained $225-240M revenue, $23-26M adj EBITDA. - **2025 Q4:** LifeVantage Q4 FY25 revenue $55.1M (+13% YoY) driven by MindBody GLP-1; international growth returns after 12 quarters; LoveBiome acquisition announced; FY26 guidance $225-240M revenue, $23-26M adj EBITDA. - **2025 Q3:** LifeVantage reports strong Q3 FY2025 with 21% revenue growth driven by US MindBody GLP-1 launch, but international declines persist; guidance maintained, supply chain issues resolved, consultant messaging pivot underway. - **2025 Q2:** LifeVantage Q2 FY25 revenue $67.8M (+31% YoY) driven by MindBody GLP-1 System launch; gross margin up 190 bps, active accounts +25% sequentially in Americas; international rollout begins March. - **2025 Q1:** LifeVantage Q1 FY2025 shows solid profitability despite 8% revenue decline, driven by strong launch of MindBody GLP-1 System with backorder demand and maintained FY2025 guidance. - **2024 Q4:** LifeVantage posted Q4 2024 revenue down ~10% but improved adjusted EBITDA margin to 9.8%, highlighted new weight‑loss system launch in October, board change and maintained FY2025 revenue/EBITDA guidance. ## Theme arcs - **Management tone** (stable): Δ mgmt=+0.10 ## Fear persistence - **macro headwinds** [recurring]: 2024 Q4, 2025 Q1 - **currency impact** [recurring]: 2024 Q4, 2025 Q1 - **regional revenue decline** [resolved]: 2024 Q4 - **weight‑management market turbulence** [resolved]: 2024 Q4 - **consultant retention risk** [resolved]: 2024 Q4 - **quarterly cadence uncertainty** [resolved]: 2024 Q4 - **product development risk** [resolved]: 2024 Q4 - **competitive pressure from affiliate models** [resolved]: 2024 Q4 - **inventory constraints** [resolved]: 2025 Q1 - **international regulatory approvals** [resolved]: 2025 Q1 ## Guidance path 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:maintained → 2026 Q3:lowered --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/LFVN`